Deranged NMDAergic cortico-subthalamic transmission underlies parkinsonian motor deficits

Journal of Clinical Investigation

Volumn 124, Issue 10, 2014, Pages 4629-4641

  Pan, Ming Kai ^a,b   Tai, Chun Hwei ^b   Liu, Wen Chuan ^b   Pei, Ju Chun ^c   Lai, Wen Sung ^c   Kuo, Chung Chin ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMATE RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; AMINO ACID RECEPTOR BLOCKING AGENT; GLUTAMATE RECEPTOR; N METHYLASPARTIC ACID;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HYPOKINESIA; LOCOMOTION; MALE; MOTOR CORTEX; MOUSE; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROTRANSMISSION; NONHUMAN; OPTOGENETICS; PARKINSONISM; PATHOPHYSIOLOGY; PREMOTOR CORTEX; RAT; SPIKE; STRIATE CORTEX; SUBTHALAMIC NUCLEUS; ANIMAL; CHEMISTRY; DISEASE MODEL; ELECTROPHYSIOLOGY; METABOLISM; MOTOR PERFORMANCE; PARKINSON DISEASE; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; ELECTROPHYSIOLOGICAL PHENOMENA; EXCITATORY AMINO ACID ANTAGONISTS; LOCOMOTION; MALE; MICE; MOTOR CORTEX; MOTOR SKILLS; N-METHYLASPARTATE; PARKINSON DISEASE; RATS; RATS, WISTAR; RECEPTORS, GLUTAMATE; SUBTHALAMIC NUCLEUS;

EID: 84907481775     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI75587     Document Type: Article

References (64)

1. De Long MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990;13(7):281-285.
2. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72 (21 suppl 4):S1-S136.
3. Kravitz AV, et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature. 2010;466(7306):622-626.
4. Fornaguera J, Huston JP, Carey RJ, Schwarting RK. Stimulation of D1- or D2-receptors in drug-naive rats with different degrees of unilateral nigro-striatal dopamine lesions. Psychopharmacology (Berl). 1995;119(2):145-154.
5. Sit SY. Dopamine agonists in the treatment of Parkinson s disease past, present and future. Curr Pharm Des. 2000;6(12):1211-1248.
6. Fleming SM, Chesselet MF. Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism. Behav Pharmacol. 2006;17(5-6):383-391.
7. Radad K, Gille G, Rausch WD. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep. 2005;57(6):701-712.
8. Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc J-L. Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26(12):2226-2231.
9. Hollerman JR, Grace AA. Subthalamic nucleus cell firing in the 6-OHDA-treated rat: basal activity and response to haloperidol. Brain Res. 1992;590(1-2):291-299.
10. Mallet N, et al. Disrupted dopamine transmission and the emergence of exaggerated beta oscillations in subthalamic nucleus and cerebral cortex. J Neurosci. 2008;28(18):4795-4806.
11. Brucke T, Djamshidian S, Bencsits G, Pirker W, Asenbaum S, Podreka I. SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol. 2000;247(suppl 4): IV/2-7.
12. Ekesbo A, Rydin E, Torstenson R, Sydow O, Laengstrom B, Tedroff J. Dopamine autoreceptor function is lost in advanced Parkinson's disease. Neurology. 1999;52(1):120-125.
13. Gresch PJ, Walker PD. Synergistic interaction between serotonin-2 receptor and dopamine D1 receptor stimulation on striatal preprotachykinin mRNA expression in the 6-hydroxydopamine lesioned rat. Brain Res Mol Brain Res. 1999;70(1):125-134.
14. Ueda H, et al. Supersensitization of neurochemical responses by L-DOPA and dopamine receptor agonists in the striatum of experimental Parkinson's disease model rats. Biomed Pharmacother. 1995;49(4):169-177.
15. Iravani MM, McCreary AC, Jenner P. Striatal plasticity in Parkinson's disease and L-dopa induced dyskinesia. Parkinsonism Relat Disord. 2012;18(suppl 1):S123-S125.
16. Nambu A, Tokuno H, Takada M. Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci Res. 2002;43(2):111-117.
17. Nambu A. A new dynamic model of the cortico-basal ganglia loop. Prog Brain Res. 2004;143:461-466.
18. Vila M, et al. Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements. Eur J Neurosci. 2000;12(1):337-344.
19. Benazzouz A, Breit S, Koudsie A, Pollak P, Krack P, Benabid AL. Intraoperative microrecordings of the subthalamic nucleus in Parkinson's disease. Mov Disord. 2002;17 (suppl 3):S145-S149.
20. Ni ZG, Bouali-Benazzouz R, Gao DM, Benabid AL, Benazzouz A. Time-course of changes in firing rates and firing patterns of subthalamic nucleus neuronal activity after 6-OHDA-induced dopamine depletion in rats. Brain Res. 2001;899(1-2):142-147.
21. Sharott A, Magill PJ, Harnack D, Kupsch A, Meissner W, Brown P. Dopamine depletion increases the power and coherence of beta-oscillations in the cerebral cortex and subthalamic nucleus of the awake rat. Eur J Neurosci. 2005;21(5):1413-1422.
22. Moran RJ, et al. Alterations in brain connectivity underlying beta oscillations in Parkinsonism. PLoS Comput Biol. 2011;7(8):e1002124.
23. Williams D, et al. Dopamine-dependent changes in the functional connectivity between basal ganglia and cerebral cortex in humans. Brain. 2002;125(pt 7):1558-1569.
24. Marsden JF, Limousin-Dowsey P, Ashby P, Pollak P, Brown P. Subthalamic nucleus, sensorimotor cortex and muscle interrelationships in Parkinson's disease. Brain. 2001;124(pt 2):378-388.
25. 2+ channels remedies locomotor deficits in a rat model of Parkinson disease. J Clin Invest. 2011;121(8):3289-3305.
26. Tai C-H, Pan M-K, Lin JJ, Huang C-S, Yang Y-C, Kuo C-C. Subthalamic discharges as a causal determinant of parkinsonian motor deficits. Ann Neurol. 2012;72(3):464-476.
27. Nakanishi H, Kita H, Kitai ST. An N-methyl-D-aspartate receptor mediated excitatory postsynaptic potential evoked in subthalamic neurons in an in vitro slice preparation of the rat. Neurosci Lett. 1988;95(1-3):130-136.
28. Nambu A, et al. Excitatory cortical inputs to pallidal neurons via the subthalamic nucleus in the monkey. J Neurophysiol. 2000;84(1):289-300.
29. Kitai ST, Deniau JM. Cortical inputs to the subthalamus: intracellular analysis. Brain Res. 1981;214(2):411-415.
30. Maurice N, Deniau JM, Glowinski J, Thierry AM. Relationships between the prefrontal cortex and the basal ganglia in the rat: physiology of the corticosubthalamic circuits. J Neurosci. 1998;18(22):9539-9546.
31. Flores G, et al. Expression of dopamine receptors in the subthalamic nucleus of the rat: characterization using reverse transcriptase-polymerase chain reaction and autoradiography. Neuroscience. 1999;91(2):549-556.
32. Campbell GA, Eckardt MJ, Weight FF. Dopaminergic mechanisms in subthalamic nucleus of rat: analysis using horseradish peroxidase and microiontophoresis. Brain Res. 1985;333(2):261-270.
33. Hassani OK, Francois C, Yelnik J, Feger J. Evidence for a dopaminergic innervation of the subthalamic nucleus in the rat. Brain Res. 1997;749(1):88-94.
34. Meibach RC, Katzman R. Catecholaminergic innervation of the subthalamic nucleus: evidence for a rostral continuation of the A9 (substantia nigra) dopaminergic cell group. Brain Res. 1979;173(2):364-368.
35. Rouzaire-Dubois B, Scarnati E. Pharmacological study of the cortical-induced excitation of subthalamic nucleus neurons in the rat: evidence for amino acids as putative neurotransmitters. Neuroscience. 1987;21(2):429-440.
36. Fujimoto K, Kita H. Response characteristics of subthalamic neurons to the stimulation of the sensorimotor cortex in the rat. Brain Res. 1993;609(1-2):185-192.
37. Heida T, Marani E, Usunoff KG. The subthalamic nucleus part II: modelling and simulation of activity. Adv Anat Embryol Cell Biol. 2008;199:1-85, vii.
38. Suri RE, Albani C, Glattfelder AH. A dynamic model of motor basal ganglia functions. Biol Cybern. 1997;76(6):451-458.
39. Gradinaru V, Mogri M, Thompson KR, Henderson JM, Deisseroth K. Optical deconstruction of parkinsonian neural circuitry. Science. 2009;324(5925):354-359.
40. Wang H, et al. High-speed mapping of synaptic connectivity using photostimulation in Channelrhodopsin-2 transgenic mice. Proc Natl Acad Sci U S A. 2007;104(19):8143-8148.
41. Arenkiel BR, et al. In vivo light-induced activation of neural circuitry in transgenic mice expressing channelrhodopsin-2. Neuron. 2007;54(2):205-218.
42. Beurrier C, Congar P, Bioulac B, Hammond C. Subthalamic nucleus neurons switch from single-spike activity to burst-firing mode. J Neurosci. 1999;19(2):599-609.
43. Overton PG, Greenfield SA. Determinants of neuronal firing pattern in the guinea-pig subthalamic nucleus: an in vivo and in vitro comparison. J Neural Transm Park Dis Dement Sect. 1995;10(1):41-54.
44. Surmeier DJ, Mercer JN, Chan CS. Autonomous pacemakers in the basal ganglia: who needs excitatory synapses anyway? Curr Opin Neurobiol. 2005;15(3):312-318.
45. Shen K-Z, Johnson SW. Chronic dopamine depletion augments the functional expression of K-ATP channels in the rat subthalamic nucleus. Neurosci Lett. 2012;531(2):104-108.
46. 2+ currents through a nitric oxide-cGMP pathway in subthalamic neurons. J Neurosci. 2010;30(5):1882-1893.
47. Petri D, Pum M, Vesper J, Huston JP, Schnitzler A. GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat. Behav Brain Res. 2013;252:58-67.
48. Parsons CG, et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology. 1995;34(10):1239-1258.
49. Huettner JE, Bean BP. Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proc Natl Acad Sci U S A. 1988;85(4):1307-1311.
50. Fogelson N, et al. Frequency dependent effects of subthalamic nucleus stimulation in Parkinson's disease. Neurosci Lett. 2005;382(1-2):5-9.
51. Chen CC, et al. Excessive synchronization of basal ganglia neurons at 20 Hz slows movement in Parkinson's disease. Exp Neurol. 2007;205(1):214-221.
52. Moro E, Esselink RJ, Xie J, Hommel M, Benabid AL, Pollak P. The impact on Parkinson's disease of electrical parameter settings in STN stimulation. Neurology. 2002;59(5):706-713.
53. Perouansky M, Yaari Y. Kinetic properties of NMDA receptor-mediated synaptic currents in rat hippocampal pyramidal cells versus interneurones. J Physiol (Lond). 1993;465:223-244.
54. Benazzouz A, Hallett M. Mechanism of action of deep brain stimulation. Neurology. 2000;55 (12 suppl 6):S13-S16.
55. Li Q, et al. Therapeutic deep brain stimulation in Parkinsonian rats directly influences motor cortex. Neuron. 2012;76(5):1030-1041.
56. Sgambato-Faure V, Cenci MA. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog Neurobiol. 2012;96(1):69-86.
57. Rouillard C, Bedard PJ, Falardeau P, Dipaolo T. Behavioral and biochemical evidence for a different effect of repeated administration of L-dopa and bromocriptine on denervated versus non-denervated striatal dopamine receptors. Neuropharmacology. 1987;26(11):1601-1606.
58. Jenner P, Marsden CD. Chronic pharmacological manipulation of dopamine receptors in brain. Neuropharmacology. 1987;26(7B):931-940.
59. Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096-1099.
60. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol. 2006;6(1):61-67.
61. Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci. 2000;20(21):7871-7879.
62. Phillips JM, Lam HA, Ackerson LC, Maidment NT. Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. Eur J Neurosci. 2006;23(1):151-160.
63. Loucif A J C, Woodhall GL, Sehirli US, Stanford IM. Depolarisation and suppression of burst firing activity in the mouse subthalamic nucleus by dopamine D1/D5 receptor activation of a cyclicnucleotide gated non-specific cation conductance. Neuropharmacology. 2008;55(1):94-105.
64. Schuepbach W M M, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013;368(7):610-622.